CA3009001A1 - Anticorps monoclonaux humainises immunostimulants diriges contre l'interleukine -2 humaine, et leurs proteines de fusion - Google Patents

Anticorps monoclonaux humainises immunostimulants diriges contre l'interleukine -2 humaine, et leurs proteines de fusion Download PDF

Info

Publication number
CA3009001A1
CA3009001A1 CA3009001A CA3009001A CA3009001A1 CA 3009001 A1 CA3009001 A1 CA 3009001A1 CA 3009001 A CA3009001 A CA 3009001A CA 3009001 A CA3009001 A CA 3009001A CA 3009001 A1 CA3009001 A1 CA 3009001A1
Authority
CA
Canada
Prior art keywords
seq
antibody
hcdr1
hcdr3
hcdr2
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3009001A
Other languages
English (en)
Inventor
Natalia Arenas-Ramirez
Iwan Beuvink
Onur Boyman
Barbara Brannetti
Andreas Katopodis
Simone POPP
Catherine Regnier
Chao ZOU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universitaet Zuerich
Original Assignee
Novartis AG
Universitaet Zuerich
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG, Universitaet Zuerich filed Critical Novartis AG
Publication of CA3009001A1 publication Critical patent/CA3009001A1/fr
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/246—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des anticorps se liant à l'interleukine -2 humaine (hIL -2). L'invention concerne plus précisément des anticorps humanisés se liant spécifiquement à un épitope particulier de l'hIL-2 et, une fois liés à cet épitope, affichant une aptitude unique à inhiber la liaison de l'hIL -2 à la CD25.
CA3009001A 2016-01-11 2017-01-11 Anticorps monoclonaux humainises immunostimulants diriges contre l'interleukine -2 humaine, et leurs proteines de fusion Pending CA3009001A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662277113P 2016-01-11 2016-01-11
US62/277,113 2016-01-11
PCT/IB2017/050127 WO2017122130A1 (fr) 2016-01-11 2017-01-11 Anticorps monoclonaux humainisés immunostimulants dirigés contre l'interleukine -2 humaine, et leurs protéines de fusion

Publications (1)

Publication Number Publication Date
CA3009001A1 true CA3009001A1 (fr) 2017-07-20

Family

ID=57882113

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3009001A Pending CA3009001A1 (fr) 2016-01-11 2017-01-11 Anticorps monoclonaux humainises immunostimulants diriges contre l'interleukine -2 humaine, et leurs proteines de fusion

Country Status (14)

Country Link
US (2) US10889643B2 (fr)
EP (1) EP3402819A1 (fr)
JP (1) JP6993699B2 (fr)
KR (1) KR20180100224A (fr)
CN (2) CN108473569B (fr)
AU (1) AU2017208133B2 (fr)
BR (1) BR112018014150A2 (fr)
CA (1) CA3009001A1 (fr)
EA (1) EA039865B1 (fr)
HK (1) HK1257518A1 (fr)
IL (1) IL260218B2 (fr)
MA (1) MA43859A (fr)
MX (1) MX2018008592A (fr)
WO (1) WO2017122130A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117700535A (zh) * 2024-02-05 2024-03-15 北京纳百生物科技有限公司 一种猫泛白细胞减少症病毒vp2蛋白单克隆抗体及其应用

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
CN106103484B (zh) * 2014-03-14 2021-08-20 诺华股份有限公司 针对lag-3的抗体分子及其用途
PL3370768T3 (pl) 2015-11-03 2022-06-13 Janssen Biotech, Inc. Przeciwciała specyficznie wiążące pd-1 i ich zastosowania
CA3013443C (fr) * 2016-02-01 2021-06-15 Eli Lilly And Company Composes de fusion parathormone-anticorps anti-rankl
CN110087681A (zh) * 2016-09-28 2019-08-02 佐马美国有限公司 结合白细胞介素-2的抗体和其用途
CA3056630A1 (fr) 2017-03-15 2018-09-20 Pandion Therapeutics, Inc. Immunotolerance ciblee
US10676516B2 (en) 2017-05-24 2020-06-09 Pandion Therapeutics, Inc. Targeted immunotolerance
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
US10174092B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
US20190225689A1 (en) * 2018-01-22 2019-07-25 Janssen Biotech, Inc. Methods of treating cancers with antagonistic anti-pd-1 antibodies
WO2019168791A2 (fr) * 2018-02-28 2019-09-06 The Board Of Trustees Of The Leland Stanford Junior University Fusions d'anticorps/il-2 à chaîne unique qui activent sélectivement des lymphocytes t régulateurs
WO2019239213A2 (fr) * 2018-06-01 2019-12-19 Medicenna Therapeutics Inc. Utilisations et procédés pour le ciblage de virus oncolytique d'il -4/il-13 et leurs fusions
KR20220035333A (ko) 2019-05-20 2022-03-22 팬디온 오퍼레이션스, 인코포레이티드 Madcam 표적 면역관용
JP7292526B2 (ja) 2020-02-16 2023-06-16 アウロス バイオサイエンス インコーポレイテッド 操作された抗ｉｌ－２抗体
US11981715B2 (en) 2020-02-21 2024-05-14 Pandion Operations, Inc. Tissue targeted immunotolerance with a CD39 effector
CN111825763B (zh) * 2020-07-15 2022-04-19 扬州大学 流感病毒ha蛋白茎部特异性单克隆抗体及其制备方法和应用
MX2023011310A (es) 2021-03-26 2023-10-05 Innate Pharma Anclajes de citocina para proteinas de celulas nk de union a nkp46.
BR112023025331A2 (pt) 2021-06-09 2024-02-27 Innate Pharma Proteína multiespecífica, composição farmacêutica, célula recombinante, ácido nucleico ou conjunto de ácidos nucleicos, uso de uma proteína ou composição, métodos ou uso
WO2022258678A1 (fr) 2021-06-09 2022-12-15 Innate Pharma Protéines multispécifiques se liant à nkp30, un récepteur de cytokine, un antigène tumoral et cd16a
WO2022258691A1 (fr) 2021-06-09 2022-12-15 Innate Pharma Protéines multispécifiques se liant à nkg2d, récepteur de cytokine, antigène tumoral et cd16a
CA3234995A1 (fr) 2021-10-14 2023-04-20 Latticon (Suzhou) Biopharmaceuticals Co., Ltd. Nouvelle proteine de fusion anticorps-cytokine, son procede de preparation et son utilisation
US11773160B1 (en) * 2022-08-05 2023-10-03 Anaveon AG Immune-stimulating IL-2 fusion proteins

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE434680B (sv) 1983-01-21 1984-08-06 Karl Arne Lundblad Anvendning av en saltlosning av monoklonala antikroppar med relativt hog salthalt vid blodgruppsbestemning
US4708871A (en) 1983-03-08 1987-11-24 Commonwealth Serum Laboratories Commission Antigenically active amino acid sequences
DK174501B1 (da) 1983-12-23 2003-04-28 Hoffmann La Roche Fremgangsmåde til fremstilling af interleukin-2
DE3572982D1 (en) 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
CA2006596C (fr) 1988-12-22 2000-09-05 Rika Ishikawa G-csf modifie chimiquement
FR2650598B1 (fr) 1989-08-03 1994-06-03 Rhone Poulenc Sante Derives de l'albumine a fonction therapeutique
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
FR2686901A1 (fr) 1992-01-31 1993-08-06 Rhone Poulenc Rorer Sa Nouveaux polypeptides antithrombotiques, leur preparation et compositions pharmaceutiques les contenant.
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US5811097A (en) 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
WO1997034631A1 (fr) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Domaines analogues a l'immunoglobuline a demi-vies prolongees
US6111090A (en) 1996-08-16 2000-08-29 Schering Corporation Mammalian cell surface antigens; related reagents
DE69738749D1 (de) 1996-08-16 2008-07-17 Schering Corp Zelloberflächen-antigen aus säugetieren und verwandte reagenzien
WO1998023289A1 (fr) 1996-11-27 1998-06-04 The General Hospital Corporation Modulation de la fixation de l'igg au fcrn
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
ES2301198T3 (es) 1997-06-12 2008-06-16 Novartis International Pharmaceutical Ltd. Polipeptidos artificiales de anticuerpos.
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
EP1025228A4 (fr) 1997-10-21 2002-09-18 Human Genome Sciences Inc Proteines tr11, tr11sv1 et tr11sv2 de type recepteur du facteur de necrose tumorale humain
US6689607B2 (en) 1997-10-21 2004-02-10 Human Genome Sciences, Inc. Human tumor, necrosis factor receptor-like proteins TR11, TR11SV1 and TR11SV2
AU2591599A (en) 1998-02-09 1999-08-23 Genentech Inc. Novel tumor necrosis factor receptor homolog and nucleic acids encoding the same
PT1196186E (pt) 1999-07-12 2008-02-14 Genentech Inc Promoção ou inibição da angiogénese e da cardiovascularização com homólogos de ligandos/receptores do factor de necrose tumoral.
CA2405709A1 (fr) 2000-04-12 2001-10-25 Human Genome Sciences, Inc. Proteines fusionnees a l'albumine
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
ES2367430T3 (es) 2002-12-23 2011-11-03 Wyeth Llc Anticuerpos contra pd-1 y sus usos.
US7387271B2 (en) 2002-12-30 2008-06-17 3M Innovative Properties Company Immunostimulatory combinations
AU2004244626A1 (en) 2003-05-23 2004-12-09 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services GITR ligand and GITR ligand-related molecules and antibodies and uses thereof
WO2005007190A1 (fr) 2003-07-11 2005-01-27 Schering Corporation Agonistes ou antagonistes du recepteur du facteur de necrose tumorale induit par les glucocorticoides (gitr) ou de son ligand utilises dans le traitement des troubles immuns, des infections et du cancer
WO2005055808A2 (fr) 2003-12-02 2005-06-23 Genzyme Corporation Compositions et methodes pour le diagnostic et le traitement du cancer du poumon
GB0409799D0 (en) 2004-04-30 2004-06-09 Isis Innovation Method of generating improved immune response
US20060002932A1 (en) 2004-06-04 2006-01-05 Duke University Methods and compositions for enhancement of immunity by in vivo depletion of immunosuppressive cell activity
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
EP2343320B1 (fr) 2005-03-25 2017-10-25 GITR, Inc. Anticorps contre gitr et leur utilisations
ES2427646T5 (es) 2005-05-09 2017-08-22 Ono Pharmaceutical Co., Ltd. Anticuerpos monoclonales humanos contra muerte programada 1 (PD1) y métodos para el tratamiento del cáncer mediante el uso de anticuerpos anti-PD-1 solos o combinados con otros agentes inmunoterapéuticos
CN101189265B (zh) 2005-06-01 2012-07-04 米克罗麦特股份公司 抗il2抗体
US20060286103A1 (en) 2005-06-15 2006-12-21 Parag Kolhe Stable antibody formulation
CN102875681A (zh) 2005-07-08 2013-01-16 拜奥根Idec马萨诸塞公司 抗-αvβ6抗体及其用途
WO2007133822A1 (fr) 2006-01-19 2007-11-22 Genzyme Corporation Anticorps anti-gitr destinés au traitement du cancer
EP1987067A4 (fr) 2006-02-15 2012-01-25 Imclone Llc Formulation d'anticorps
SG170001A1 (en) * 2006-02-16 2011-04-29 Nascent Biolog Inc Methods for improving immune function and methods for prevention or treatment of disease in a mammalian subject
RS53072B (en) 2007-06-18 2014-04-30 Merck Sharp & Dohme B.V. HUMAN RECEPTOR ANTIBODIES PROGRAMMED DEATH PD-1
JP5932217B2 (ja) 2007-07-12 2016-06-08 ジーアイティーアール， インコーポレイテッド Ｇｉｔｒ結合分子を使用する併用療法
PT2242773T (pt) 2008-02-11 2017-09-15 Cure Tech Ltd Anticorpos monoclonais para o tratamento de tumores
EP2262837A4 (fr) 2008-03-12 2011-04-06 Merck Sharp & Dohme Protéines de liaison avec pd-1
WO2010003118A1 (fr) 2008-07-02 2010-01-07 Trubion Pharmaceuticals, Inc. Protéines de liaison multi-cibles antagonistes du tgf-b
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
WO2010027423A2 (fr) 2008-08-25 2010-03-11 Amplimmune, Inc. Compositions d'antagonistes de pd-1 et methodes d'utilisation associees
EP2328919A2 (fr) 2008-08-25 2011-06-08 Amplimmune, Inc. Antagonistes de pd-i et procédés de traitement d'une maladie infectieuse
US8586023B2 (en) 2008-09-12 2013-11-19 Mie University Cell capable of expressing exogenous GITR ligand
EP2473531A4 (fr) 2009-09-03 2013-05-01 Merck Sharp & Dohme Anticorps anti-gitr
GB0919054D0 (en) 2009-10-30 2009-12-16 Isis Innovation Treatment of obesity
US20130017199A1 (en) 2009-11-24 2013-01-17 AMPLIMMUNE ,Inc. a corporation Simultaneous inhibition of pd-l1/pd-l2
AU2010343057B2 (en) 2009-12-29 2017-02-23 Aptevo Research And Development Llc Heterodimer binding proteins and uses thereof
EP3363499A1 (fr) 2010-06-11 2018-08-22 Kyowa Hakko Kirin Co., Ltd. Anticorps anti-tim-3
PL3042917T3 (pl) 2010-08-12 2018-07-31 Eli Lilly And Company Przeciwciała przeciwko peptydowi beta amyloidu N3pGlu i ich zastosowanie
HUE029139T2 (hu) 2011-02-10 2017-02-28 Roche Glycart Ag Mutáns interleukin-2 polipeptidek
WO2013039954A1 (fr) 2011-09-14 2013-03-21 Sanofi Anticorps anti-gitr
WO2013158292A1 (fr) 2012-04-17 2013-10-24 University Of Washington Through Its Center For Commercialization Cellules déficientes en hla de classe ii, cellules déficientes en hla de classe i aptes à exprimer des protéines de hla de classe ii, et leurs utilisations
WO2013157105A1 (fr) 2012-04-18 2013-10-24 公立大学法人大阪市立大学 Anticorps humain spécifique de mucine 5ac et son utilisation
KR101566538B1 (ko) 2012-06-08 2015-11-05 국립암센터 신규한 Ｔｈ17 세포 전환용 에피토프 및 이의 용도
UY34887A (es) 2012-07-02 2013-12-31 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
CN112587671A (zh) 2012-07-18 2021-04-02 博笛生物科技有限公司 癌症的靶向免疫治疗
CN105188373B (zh) 2013-05-18 2017-09-22 艾杜罗生物科技公司 抑制“干扰素基因刺激蛋白”依赖性信号传导的组合物和方法
MY175308A (en) 2013-05-18 2020-06-18 Aduro Biotech Inc Compositions and methods for activating "stimulator of interferon gene"-dependent signalling
AR097306A1 (es) 2013-08-20 2016-03-02 Merck Sharp & Dohme Modulación de la inmunidad tumoral
WO2015109212A1 (fr) 2014-01-17 2015-07-23 Pfizer Inc. Anticorps anti-il-2 et compositions et utilisations de ceux-ci
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
CN106103484B (zh) 2014-03-14 2021-08-20 诺华股份有限公司 针对lag-3的抗体分子及其用途
EP3693389A1 (fr) * 2014-07-10 2020-08-12 Universität Zürich Anticorps monoclonaux ayant une activité immunostimulante contre l'interleukine-2 humaine

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117700535A (zh) * 2024-02-05 2024-03-15 北京纳百生物科技有限公司 一种猫泛白细胞减少症病毒vp2蛋白单克隆抗体及其应用
CN117700535B (zh) * 2024-02-05 2024-04-26 北京纳百生物科技有限公司 一种猫泛白细胞减少症病毒vp2蛋白单克隆抗体及其应用

Also Published As

Publication number Publication date
IL260218B (en) 2022-12-01
US11851484B2 (en) 2023-12-26
CN108473569B (zh) 2022-11-22
AU2017208133B2 (en) 2023-12-21
AU2017208133A1 (en) 2018-07-05
CN116003593A (zh) 2023-04-25
US20210246200A1 (en) 2021-08-12
CN108473569A (zh) 2018-08-31
US20190016797A1 (en) 2019-01-17
MA43859A (fr) 2018-11-21
EA201891582A1 (ru) 2018-12-28
HK1257518A1 (zh) 2019-10-25
JP2019511200A (ja) 2019-04-25
EP3402819A1 (fr) 2018-11-21
KR20180100224A (ko) 2018-09-07
WO2017122130A1 (fr) 2017-07-20
BR112018014150A2 (pt) 2018-12-11
IL260218A (en) 2018-07-31
US10889643B2 (en) 2021-01-12
EA039865B1 (ru) 2022-03-22
JP6993699B2 (ja) 2022-02-03
IL260218B2 (en) 2023-04-01
WO2017122130A9 (fr) 2018-02-01
MX2018008592A (es) 2018-12-10

Similar Documents

Publication Publication Date Title
US11851484B2 (en) Immune-stimulating humanized monoclonal antibodies against human interleukin-2, and fusion proteins thereof
JP7345578B2 (ja) 新規抗ｐｄ－ｌ１抗体
CN111867630B (zh) 靶向cldn18.2的抗体、双特异性抗体、adc和car及其应用
ES2824167T3 (es) Anticuerpos anti-CD3, anticuerpos anti-CD123 y anticuerpos biespecíficos que se unen específicamente a CD3 y/o CD123
CN108350076B (zh) 抗-bcma抗体，结合bcma和cd3的双特异性抗原结合分子及其用途
CN109476756B (zh) 一种多特异性Fab融合蛋白及其用途
CN110606891A (zh) 一种针对人cldn18.2的新型抗体分子, 抗原结合片段及其医药用途
WO2020228806A1 (fr) Anticorps dirigé contre la claudine 18a2 et son utilisation
KR20220050971A (ko) 신규 항-cd39 항체
US20230295301A1 (en) Anti-ctla-4 antibody and use thereof
CN113454119A (zh) 抗btla抗体
CN110172099B (zh) 抗lag-3人源化单克隆抗体分子，抗原结合片段及其医药用途
KR20180021875A (ko) 다중특이적 결합 단백질
TWI818916B (zh) 抗ｃｄ１４７抗體、及其用途與製造方法
KR20220145854A (ko) 지방산 분자와 접합된 항체 및 이의 용도
WO2022100613A1 (fr) Anticorps bispécifique pour claudin 18a2 et cd3 et application d'un anticorps bispécifique

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20211220

EEER Examination request

Effective date: 20211220

EEER Examination request

Effective date: 20211220

EEER Examination request

Effective date: 20211220

EEER Examination request

Effective date: 20211220

EEER Examination request

Effective date: 20211220